xeloda

Objective To observe therapeutic effect and toxicity of the combination of xeloda with weekly dose of oxaliplatin in treatment of patients with advanced enteron tumor.

目的观察希罗达联合周剂量艾恒治疗晚期消化道肿瘤的疗效和毒副反应。

Clinical Observation to Postoperative Recurrence of Rectal Cancer Treated with Three Dimensional-conformal Radiotherapy Combined with Xeloda

三维适形放疗同步希罗达化疗治疗直肠癌术后复发的临床观察

Methods: Xeloda 2 500 mg/ m 2/ day in dividing two dose per oral continued for two weeks, then stopped for one to two weeks.

方法：希罗达2500mg/m2·d-1，分2次口服，连续口服2周，停药1～2周；

Efficacy of postoperative concurrent radiotherapy and chemotherapy with Xeloda for stage ⅱ/ ⅲ rectal cancer

Ⅱ、Ⅲ期直肠癌根治术后放疗同步希罗达化疗的疗效

Fifty-Two Patients with Metastatic Cervical Carcinoma Treated with Paclitaxel Plus Xeloda

卡培他滨联合紫杉醇治疗晚期转移性宫颈癌的临床研究

The Clinical Study of Celecoxib Combined with Xeloda Metronomic Chemotherapy in the Treatment of the Elderly with Advanced Gastric Cancer

塞来昔布/希罗达节拍化疗治疗老年晚期胃癌的临床研究

In the xeloda group, diarrhea in 28%, stomatitis in 16. 6% and hand-foot syndrome in 38. 9%.

希罗达组副反应主要为腹泻（28%）、手足综合征（38.9%）和口炎（16.6%）。

Objective: The effect of Xeloda combined with traditional Chinese Medicine Shen Ling Bai Zhu Decoction on the prognosis and Quality Of Life of elderly advanced colorectal carcinoma.

目的：观察希罗达（Xeloda）加中药参苓白术汤对晚期结直肠癌预后及生活质量的影响。

Clinical Observation of 33 Patients with Advanced Breast Cancer Treated with Docetaxel and Xeloda

多西紫杉醇联合希罗达治疗晚期乳腺癌33例临床观察

AIM: To investigate the effect of capecitabine ( xeloda) by preoperation administration on the microvessel density ( MVD) and expression of thymidine phosphorylase/ platelet-derived endothelial cell growth factor ( TP/ PD-ECGF) in patients with colorectal cancer.

目的：探讨术前希罗达化疗对结直肠癌胸苷磷酸化酶/血小板衍化内皮细胞生长因子（TP/PD-ECGF）表达、肿瘤组织微血管密度（MVD）的影响。

Xeloda is licensed for the first-line treatment of stomach cancer that has spread, in South Korea.

希罗达已在韩国获得授权,用于 一线 治疗已扩散的胃癌.

Progress of Study on Prevention and Treatment of Xeloda Induced Hand-foot Syndrome by Measures of Chinese and Western Medicine

希罗达等致手足综合征中、西医防治措施研究进展

Capecitabine ( trade name" Xeloda") was first listed in Switzerland in August 1998.

卡培他滨于1998年8月在瑞士首次上市，商品名为Xeloda。

Objective To evaluate the response rate and adverse reaction of metastatic and recurrent breast cancer patients treated with xeloda.

目的观察希罗达治疗转移性或复发性乳腺癌的疗效及不良反应。

METHODS: Immunohistochemical staining of CD34 and TP/ PD-ECGF monoclonal antibodies was performed in 32 colorectal cancer patients with preoperative xeloda chemotherapy and 25 cases without chemotherapy ( served as con-trols), and then the expression of TP/ PD-ECGF and MVD were analyzed.

方法：对32例术前应用希罗达化疗的和25例未做术前化疗的结直肠癌标本，进行TP/PD-ECGF、CD34免疫组织化学标记，检测其TP/PD-ECGF表达及微血管密度MVD。

Xeloda combined with oxaliplatin in the treatment of advanced colorectal cancer

希罗达联合奥沙利铂治疗晚期结直肠癌的临床观察

The Clinical Observation of Xeloda Combined with Taxotere in the Treatment of Advanced Gastric Cancer

希罗达联合泰素帝治疗晚期胃癌的疗效观察

Objective : To observe effect and side-effect in 20 advanced-breast cancers cure using Xeloda and Docetaxel.

目的: 观察以希罗达为主的联合多希紫杉醇治疗晚期乳腺癌的疗效及毒副反应.

Experimental Study on Changes of Expression of AFP mRNA in Human Hepatocellular Carcinoma Tissues after Oral Xeloda Therapy

希罗达对人肝癌组织AFP mRNA表达影响的实验研究

Xeloda is a highly effective oral chemotherapy drug that can be used alone, or in combination with other drugs, for the treatment of colorectal ( including colon), stomach and breast cancer.

希罗达不管是单药还是联合其他药物在治疗结直肠癌（包括结肠癌）、胃癌、乳腺癌方面是非常高效的口服化疗药物。

CONCLUSION: Preoperation chemotherapy of xeloda can decrease the activity of TP/ PD-ECGF and inhibit the angiogenesis in colorectal cancer.

结论：希罗达术前化疗能使TP/PD-ECGF活性降低，抑制结直肠癌肿瘤血管生成。

Study on regularity and treatment of hand-foot syndrome induced by xeloda as a therapy to breast cancer

希罗达治疗乳腺癌所致手足综合征的发生规律及临床处理

Clinical Studies of oxaliplatin and capecitabine ( Xeloda) in the treatment of elderly patients with Advanced Gastric carcinoma

奥沙利铂联合卡培他滨治疗老年晚期胃癌的临床研究

It was began the registration of clinical trials in Beijing, Shanghai, Guangzhou and other places of the five national anticancer drug ′ s clinical trial research centers in November 1999. Then it was listed in China as the trade name "Xeloda".

于1999年11月开始由北京、上海、广州等地的5个国家抗肿瘤药物临床试验研究中心进行注册临床试验，并以商品名希罗达在中国上市。

Objective: to observe the clinical effect of TCM Drug Huwei Yufu Decoction in treating xeloda related hand-foot syndrome.

目的：观察中药护胃愈肤汤治疗希罗达相关性手足综合症临床疗效。

Xeloda is a chemotherapy pill that kills cancerous cells. Avastin cuts off blood-flow to tumors.

希罗达是可以杀死癌细胞的化疗药物, 而阿伐斯汀却能切断肿瘤血管.

The Observation of Safety and Efficacy of Continuous-Infusion 5-Fluorouracil Versus Xeloda for Gastrointestinal Cancer

5-Fu静脉泵持续输注与口服希罗达治疗消化道肿瘤的安全性及疗效的观察

Clinical observation of 36 cases with metastatic breast cancer treated by xeloda combining with with docetaxel

希罗达联合多西他赛治疗转移性乳腺癌36例临床观察

Conclusion Xeloda is suitable for the chemotherapy of malignant solid tumor of digestive tract.

结论希罗达可能适宜用于消化道恶性实体肿瘤化疗。

Docetaxel and Xeloda Combined Chemotherapy in Anthracyclines Resistant Advanced Breast Cancer

多西他赛联合希罗达治疗蒽环类耐药性晚期乳腺癌